Annexon shares rise on positive Guillain-Barré study results

Shares of Annexon Inc experienced a 12% increase following the announcement of positive topline results from a study evaluating its immunotherapy ANX005.

The drug developer reported that the study’s findings support the potential of ANX005 as a treatment option for Guillain-Barré Syndrome, a rare and acute neuromuscular disease.

The study in question was a real-world evidence study that compared the effects of ANX005 with those of intravenous immunoglobulin within a matched patient cohort.

The goal was to assess the efficacy of ANX005 in treating Guillain-Barré Syndrome, which currently lacks FDA-approved treatments.

The company’s shares responded favorably to the news, reflecting investor optimism about the potential market opportunity for ANX005.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.